Global Cancer Antibody Drug Conjugates Market Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, Oct. 23, 2024 ...

This year, nearly 10,000 children age 15 and younger in the U.S. are expected to be diagnosed with cancer. As these children ...

The global cytotoxic drugs market is on the cusp of remarkable expansion, with projections indicating a substantial increase in market value to USD 18.3 billion by 2033, up from USD 16.3 billion in ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

DelveInsight's 'Antibody-drug Conjugates in Oncology Competitive Landscape – 2024' report provides comprehensive global ...

Researchers hope to plan clinical trials of 5-fluorouracil with drugs that would enhance its RNA-damaging effects and kill ...

In clinical trials, SA13CA has shown significant efficacy and durable response rates in patients with relapsed or refractory CTCL and PTCL. Additionally, in patients with ALL, SA13CA has demonstrated ...

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.

Redispensing unused oral cancer drugs reduces waste and improves the environmental sustainability of cancer treatment, a study suggests.

ADCs are a group of targeted cancer drugs made from a combination of monoclonal antibodies, which help to target the treatment towards cancerous cells, and a cytotoxic drug, which kills those cells.

DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that ...